181 related articles for article (PubMed ID: 19671749)
21. Key amino acid residue in Melanocortin-1 receptor (melanocyte α-MSH receptor) for ligand selectivity.
Yang Y; Chen M; Ventro G; Harmon CM
Mol Cell Endocrinol; 2017 Oct; 454():69-76. PubMed ID: 28579117
[TBL] [Abstract][Full Text] [Related]
22. Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors.
Josan JS; Vagner J; Handl HL; Sankaranarayanan R; Gillies RJ; Hruby VJ
Int J Pept Res Ther; 2008 Dec; 14(4):293-300. PubMed ID: 19714261
[TBL] [Abstract][Full Text] [Related]
23. Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.
Molden BM; Cooney KA; West K; Van Der Ploeg LH; Baldini G
Mol Endocrinol; 2015 Nov; 29(11):1619-33. PubMed ID: 26418335
[TBL] [Abstract][Full Text] [Related]
24. Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.
Sharma S; Garfield AS; Shah B; Kleyn P; Ichetovkin I; Moeller IH; Mowrey WR; Van der Ploeg LHT
Molecules; 2019 May; 24(10):. PubMed ID: 31100979
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
[TBL] [Abstract][Full Text] [Related]
26. Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalization.
Hong MH; Xu C; Wang YJ; Ji JL; Tao YM; Xu XJ; Chen J; Xie X; Chi ZQ; Liu JG
J Neurochem; 2009 Jan; 108(1):102-14. PubMed ID: 19014372
[TBL] [Abstract][Full Text] [Related]
27. Homogeneous fluorescence anisotropy-based assay for characterization of ligand binding dynamics to GPCRs in budded baculoviruses: the case of Cy3B-NDP-α-MSH binding to MC4 receptors.
Veiksina S; Kopanchuk S; Mazina O; Link R; Lille A; Rinken A
Methods Mol Biol; 2015; 1272():37-50. PubMed ID: 25563175
[TBL] [Abstract][Full Text] [Related]
28. Discovery and in vivo evaluation of new melanocortin-4 receptor-selective peptides.
Nijenhuis WA; Kruijtzer JA; Wanders N; Vrinten DH; Garner KM; Schaaper WM; Meloen RH; Gispen WH; Liskamp RM; Adan RA
Peptides; 2003 Feb; 24(2):271-80. PubMed ID: 12668212
[TBL] [Abstract][Full Text] [Related]
29. A Surprising Recipe for Designing Biased Ligands.
Topiol S
J Med Chem; 2019 Jan; 62(1):141-143. PubMed ID: 29863866
[TBL] [Abstract][Full Text] [Related]
30. Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions.
Handl HL; Vagner J; Yamamura HI; Hruby VJ; Gillies RJ
Anal Biochem; 2004 Jul; 330(2):242-50. PubMed ID: 15203329
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptor.
Ying J; Gu X; Cai M; Dedek M; Vagner J; Trivedi DB; Hruby VJ
J Med Chem; 2006 Nov; 49(23):6888-96. PubMed ID: 17154518
[TBL] [Abstract][Full Text] [Related]
32. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological analyses of two naturally occurring porcine melanocortin-4 receptor mutations in domestic pigs.
Fan ZC; Sartin JL; Tao YX
Domest Anim Endocrinol; 2008 May; 34(4):383-90. PubMed ID: 18262384
[TBL] [Abstract][Full Text] [Related]
34. Squalene-derived flexible linkers for bioactive peptides.
Jagadish B; Sankaranarayanan R; Xu L; Richards R; Vagner J; Hruby VJ; Gillies RJ; Mash EA
Bioorg Med Chem Lett; 2007 Jun; 17(12):3310-3. PubMed ID: 17448660
[TBL] [Abstract][Full Text] [Related]
35. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.
Xiang Z; Pogozheva ID; Sorenson NB; Wilczynski AM; Holder JR; Litherland SA; Millard WJ; Mosberg HI; Haskell-Luevano C
Biochemistry; 2007 Jul; 46(28):8273-87. PubMed ID: 17590021
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist.
Xiang Z; Litherland SA; Sorensen NB; Proneth B; Wood MS; Shaw AM; Millard WJ; Haskell-Luevano C
Biochemistry; 2006 Jun; 45(23):7277-88. PubMed ID: 16752916
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and in vitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC
Lindner S; Fiedler L; Wängler B; Bartenstein P; Schirrmacher R; Wängler C
Eur J Med Chem; 2018 Jul; 155():84-95. PubMed ID: 29864700
[TBL] [Abstract][Full Text] [Related]
38. Characterization of melanocortin receptors.
Goetz AS; Ignar DM
Curr Protoc Pharmacol; 2003 Nov; Chapter 1():Unit1.28. PubMed ID: 21956799
[TBL] [Abstract][Full Text] [Related]
39. Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues.
Li SZ; Lee JH; Lee W; Yoon CJ; Baik JH; Lim SK
Eur J Biochem; 1999 Oct; 265(1):430-40. PubMed ID: 10491201
[TBL] [Abstract][Full Text] [Related]
40. Evidence for a mu-delta opioid receptor complex in CHO cells co-expressing mu and delta opioid peptide receptors.
Rutherford JM; Wang J; Xu H; Dersch CM; Partilla JS; Rice KC; Rothman RB
Peptides; 2008 Aug; 29(8):1424-31. PubMed ID: 18472184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
